RxDoctor Payments Data

David Auringer, MD

Ophthalmology · Albany, NYNPI 1184941221

Payments from drug & device makers

$731in general payments, 2019–2025

Across 24 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$333
  • Alcon$228
  • Biotissue Holdings Inc.$39
  • Omeros Corporation$38
  • Novartis$19
  • Kala Pharmaceuticals, Inc.$16
  • plus $58 from 4 others

What the payments were for

  • Food & beverage$66090%
  • Education$7010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$731 in reported general payments places this provider in the 40th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$665,695
Medicare patients
871
Services billed
3,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost126$69,285
XiidraLifitegrast24$43,394
CombiganBrimonidine Tartrate/Timolol55$28,679
RestasisCyclosporine17$26,124
Alphagan PBrimonidine Tartrate28$16,154
Cyclosporine22$11,802
RhopressaNetarsudil Mesylate24$10,266
Timolol Maleate125$8,457
Prednisolone Acetate255$7,538
Latanoprost295$5,140
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$4,960
Loteprednol Etabonate16$2,914
Brimonidine Tartrate31$2,832
Tobramycin-DexamethasoneTobramycin/Dexamethasone65$2,745
Dorzolamide Hcl96$2,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$15$43,39424 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$14$2,91416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →